Dyne Therapeutics Reports Q1 Results, Confirms DMD BLA Submission on Track for Q2 2026, Extends Cash Runway
DYN has more than doubled off its 52-week low of $8.06.
Summary
Dyne Therapeutics reported Q1 2026 financial results, including a net loss of $(120.9) million, while reaffirming its cash runway into Q1 2028 and providing positive updates on its lead clinical programs for DMD and DM1, including BLA submission timelines.
Key Events · Earnings and Guidance · DYN
-
Q1 2026 Financial Results
Reported a net loss of $(120.9) million, or $(0.73) per diluted share, for Q1 2026. R&D expenses decreased to $100.9 million, while G&A expenses increased to $24.4 million due to launch preparation.
-
Cash Runway Extended
Cash, cash equivalents, and marketable securities stood at $972.2 million as of March 31, 2026, sufficient to fund operations into Q1 2028.
-
DMD Program (z-rostudirsen) on Track for BLA Submission
Completed a positive pre-BLA meeting with the FDA and remains on track to submit a Biologics License Application (BLA) for U.S. Accelerated Approval in Q2 2026, with a potential U.S. launch in Q1 2027. A global confirmatory Phase 3 trial will also initiate in Q2 2026.
-
DM1 Program (z-basivarsen) Advances
Reached the enrollment target of 60 participants in the ACHIEVE registrational expansion cohort, with data expected in Q1 2027 to support a potential BLA submission in early Q3 2027. The global confirmatory Phase 3 HARMONIA trial was initiated in March 2026.
Analysis · DYN · Life Sciences
This filing is highly important as it provides a comprehensive update on Dyne Therapeutics' financial health and, more critically, its clinical pipeline. The confirmation of a positive pre-BLA meeting and the timeline for BLA submission for its Duchenne muscular dystrophy (DMD) program (z-rostudirsen) in Q2 2026, with a potential launch in Q1 2027, represents a significant de-risking event and a major step towards commercialization. Simultaneously, the DM1 program (z-basivarsen) is also advancing well, with enrollment targets met and a Phase 3 trial initiated. The extended cash runway into Q1 2028 provides financial stability to execute on these critical milestones.
At the time of this filing, DYN was trading at $17.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.